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Background: Clarithromycin, amoxicillin, metronidazole, tetracycline, and levofloxacin 
have been commonly used for the eradication of Helicobacter pylori. We compared the 
change in antibiotic resistance of H. pylori strains during two separate periods and investi-
gated the effect of antibiotic resistance on H. pylori eradication.
Methods: H. pylori strains were isolated from 71 patients between 2009 and 2010 and 
from 94 patients between 2011 and 2012. The distribution of minimal inhibitory concen-
tration (MIC) of 5 antibiotics was assessed using the agar dilution method, and H. pylori 
eradication based on the antimicrobial susceptibility of the isolates was investigated retro-
spectively.
Results: Antibiotic resistance rate against clarithromycin, amoxicillin, tetracycline, metro-
nidazole, and levofloxacin for the 2009-2010 isolates were 7.0% (5/71), 2.8% (2/71), 0% 
(0/71), 45.1% (32/71), and 26.8% (19/71), respectively, and for the 2011-2012 isolates 
were 16.0% (15/94), 2.1% (2/94), 0% (0/94), 56.3% (53/94), and 22.3% (21/94), re-
spectively. Multi-drug resistance for 2 or more antibiotics increased slightly from 16.9% 
(12/71) in the 2009-2010 isolates to 23.4% (22/94) in the 2011-2012 isolates. In follow-
up testing of 66 patients, first-line treatment successfully eradicated H. pylori in 50 pa-
tients (75.8%) and failed in 4 of 7 patients (57.1%) in a clarithromycin-resistant and 
amoxicillin-susceptible group.
Conclusions: We observed an increase in resistance to clarithromycin and an overall in-
crease in multi-drug resistance during the 2 study periods. The effectiveness of the eradi-
cation regimen was low with combinations of clarithromycin and amoxicillin, particularly in 
the clarithromycin-resistant group. Thus, eradication of H. pylori depends upon periodic 
monitoring of antimicrobial susceptibility.
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INTRODUCTION
Eradication of gastric colonies of Helicobacter pylori helps heal 
gastritis and peptic ulcer disease and has beneficial effects on 
the regression of atrophic gastritis and the prevention of distal 
gastric cancer [1, 2]. Triple therapy using a proton pump inhibi-
tor (PPI) with clarithromycin and amoxicillin or metronidazole is 
recommended as the first-line treatment regimen for H. pylori 
eradication. If it fails, bismuth-containing quadruple therapy, 
which involves inclusion of additional antibiotics to the first-line 
An B, et al.
Antibiotic resistance and eradication of H. pylori
416  www.annlabmed.org http://dx.doi.org/10.3343/alm.2013.33.6.415
treatment regimen is used [3, 4]. The increase in clarithromycin 
resistance in Korea is considered to be closely related to the de-
crease of eradication rate in first-line therapy. According to re-
cent data, clarithromycin resistance sharply increased from 
16.7% to 38.5% from 2003 through 2009, and eradication 
rates have decreased by 77-87% since 2003 [4-6]; these rates 
are inclusive of regional and institutional differences. 
 Although regular antibiotic resistance monitoring is important 
in the clinical setting, the labor-intensive and time-consuming 
nature of H. pylori isolation from clinical samples complicates 
comparative antibiotic susceptibility testing. In this study, we in-
vestigated H. pylori antibiotic resistance and its effect on eradi-
cation rates in a single center in Korea between 2009-2010 and 
2011-2012.
METHODS
1. Patients
H. pylori strains were isolated from 71 patients with H. pylori in-
fections from July 2009 to December 2010 and from 94 pa-
tients from June 2011 through December 2012 at the Yongin 
Severance Hospital of Yonsei University, Korea. Of these pa-
tients, 66 (clinical characteristics listed in Table 1) had previ-
ously undergone eradication treatments, including week-long 
first-line treatment with PPI (pantoprazole or esomeprazole 30 
mg, bid), amoxicillin (2,250 mg, tid), clarithromycin (1,000 mg, 
bid). First-line therapy failed in 16 patients, and they were sub-
jected to second-line treatment with PPI (30 mg, bid), bismuth 
(300 mg, bid), metronidazole (2,250 mg, bid), and tetracycline 
(1,000 mg, qid). Eradication of H. pylori was verified by a nega-
tive result in a 13C-urea breath test (Isotechnika, Alberta, Can-
ada) after at least 4 weeks of drug administration.
 This study was conducted retrospectively to follow up the re-
sults of eradication of H. pylori on the basis of antimicrobial sus-
ceptibility of the isolates, and it did not interfere with patient 
management decisions. The study was approved by the Institu-
tional Review Board of Yonsei University College of Medicine 
(No. 4-2011-0508). Written informed consent was provided by 
all patients at the time of their first visit to the hospital.
2. H. pylori culture
The culture medium used in this study was composed of Bru-
cella broth (BBL, Sparks, MD, USA) containing 1.2% agar, 10% 
bovine serum, and selected antibiotics (Oxoid Limited, Hamp-
shire, England) (10 µg/mL vancomycin, 5 µg/mL trimethoprim, 
5 µg/mL cefsulodin, and 5 µg/mL amphotericin B). Completely 
minced gastric biopsy specimens were incubated under 10% 
CO2, 5% O2, and 100% humidity at 37°C for 3-5 days. Strains 
were identified as H. pylori by Gram staining; colony morphol-
ogy analysis; and oxidase, catalase, and urease tests. The H. 
pylori ATCC 43504 strain was cultured as a standard using the 
same methods described above for quality control assessment.
3. Susceptibility tests
The minimal inhibitory concentrations (MICs) for clarithromycin 
(Sigma-Aldrich Co., St. Louis, MO, USA), amoxicillin (Sigma-Al-
drich), tetracycline (Sigma-Aldrich), metronidazole (Sigma-Al-
drich), and levofloxacin (Sigma-Aldrich) were determined using 
a slightly modified agar dilution method (using Brucella broth 
base containing 1.2% agar). Clarithromycin resistance was de-
fined according to the CLSI-approved breakpoint (≥1 µg/mL) 
[7]. Isolates were defined as resistant to amoxicillin, tetracycline, 
metronidazole, and levofloxacin, when MICs were ≥1, ≥4, ≥8, 
and ≥1 µg/mL, respectively [8-10].
 For H. pylori ATCC 43504, the MIC ranges for clarithromycin, 
amoxicillin, metronidazole, tetracycline, and levofloxacin were 
0.016-0.125 µg/mL, 0.016-0.125 µg/mL, 64-256 µg/mL, 0.125- 
1 µg/mL, and 0.064-0.5 µg/mL, respectively.
4. Statistical analysis
Statistical analysis was performed using SPSS (Statistical Pack-
age for the Social Sciences version 18.0; SPSS Ins., Chicago, IL, 
USA). Data of antibiotic resistance were analyzed using the stu-
dent t test and Chi-square test. P <0.05 was considered statisti-
cally significant.
RESULTS
1. Antibiotic resistance of H. pylori
The antibiotic resistance rates for the isolates from the 2009-
2010 group against clarithromycin, amoxicillin, tetracycline, met-
Table 1. Clinical characteristics of patients with a history of eradica-
tion treatments
Patients (N=66)
Sex Male 26
Female 40
Age (mean±SD) Male   51.7±15.7
Female 52.0±9.8
Endoscopic diagnosis PUD 29
NUD 37
Values are presented as number or mean±SD.
Abbreviations: PUD, peptic ulcer disease; NUD, non ulcer disease.
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from 45.1% to 56.3% for the 2 periods, respectively (Fig. 1), al-
though the increase was not statistically significant.
 When the MIC distribution profiles for the 2 study periods 
were compared, the MICs for clarithromycin showed notable dif-
ferences between the susceptible and resistant strains (Fig. 2). 
The MIC of the clarithromycin-susceptible strains was less than 
0.125 µg/mL. Resistance to tetracycline was not detected in any 
strain (based on a cut-off of ≥ 4 µg/mL). The MIC range of tetra-
cycline was 0.031-2 µg/mL. The MIC of metronidazole varied 
widely (8-256 µg/mL). Multi-drug resistance for 2 or more antibi-
otics was more frequent in the isolates from 2011-2012 (23.4%, 
22/94) than in the isolates from 2009-2010 (16.9%, 12/71), but 
there was no statistical significance (P <0.082). Only 1 strain ex-
hibited multi-drug resistance to clarithromycin, amoxicillin, met-
ronidazole, and levofloxacin (Table 2).
2.  Effect of antibiotic resistance on H. pylori eradication rates
Of the 165 patients studied during the 2009-2012 period, 66 
patients who were subjected to the first-line therapy were fol-
lowed up for H. pylori eradication after treatment. Among these 
ronidazole, and levofloxacin were 7.0% (5/71), 2.8% (2/71), 0% 
(0/71), 45.1% (32/71), and 26.8% (19/71), respectively, and 
those for the isolates from the 2011-2012 group were 16.0% 
(15/94), 2.1% (2/94), 0% (0/94), 56.3% (53/94), and 22.3% 
(21/94), respectively. The rate of H. pylori resistance to clarithro-
mycin and metronidazole increased from 7.0% to 16.0% and 
Fig. 1. Antibiotic resistance in H. pylori strains isolated during 2009-
2010 and 2011-2012. Increased antibiotic resistance was notable 
in clarithromycin and metronidazole, although there was no statisti-
cal difference. 
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66 patients, no significant differences were found with respect to 
sex, age, and endoscopic diagnosis. Eradication of H. pylori was 
successful in 50 of these 66 patients (75.8%). The effects of an-
tibiotic resistance on H. pylori eradication rates are shown in Ta-
ble 3. Eradication rates were 79.3% (46/58) for the clarithromy-
cin-susceptible and amoxicillin-susceptible strains, and 100% 
(1/1) for the clarithromycin-susceptible and amoxicillin-resistant 
strains. A significant difference was observed between the eradi-
cation rates for the clarithromycin-resistant (42.9%, 3/7) and the 
clarithromycin-sensitive (79.7%, 47/59) strains (P <0.001) .
 Second-line therapy was prescribed for the 16 patients in 
whom first-line therapy failed. The eradication rates for the tet-
racycline-susceptible and metronidazole-susceptible strains and 
the tetracycline-susceptible and metronidazole-resistant strains 
were 50.0% (4/8) and 25.0% (2/8), respectively (P <0.32).
DISCUSSION
Recently, H. pylori eradication rates of 70-95% have been re-
ported [4-6]. Failure of eradication may be attributed to increase 
in antibiotic resistance associated with problems in patient com-
pliance, such as difficulties in taking drugs, or side effects [11-
13]. In this study, the antimicrobial susceptibility test was con-
ducted for H. pylori strains isolated from a single center over 2 
periods, followed by examination of the factors affecting failure.
 Clarithromycin resistance rates increased from 7.0% in the 
2009-2010 patient group to 16.0% in the 2011-2012 patient 
group. These rates are slightly lower than that reported in a pre-
vious study, which showed that the overall frequency of clar-
ithromycin-resistant H. pylori in 2008 was 21.6% [14]. This dis-
crepancy is conceivably attributable to regional differences in 
the location of the studies. The primary factor influencing clar-
ithromycin resistance is known to be the A2142-4 point muta-
tion in the 23S rRNA [14-17]. 
 Amoxicillin resistance rates decreased slightly from 2.8% 
(2009-2011) to 2.1% (2011-2012). Resistance to tetracycline 
was not detected in any strain when the cut-off was set at ≥ 4 
μg/mL, and the MICs were as low as 0.031-2 μg/mL. Recently, 
tetracycline resistance rates of 0-36% have been reported. How-
ever, as with clarithromycin resistance, the differences could be 
due to regional differences [18, 19]. Metronidazole resistance 
rates were higher than those for all other antibiotics, ranging from 
45.1% in the 2009-2010 group to 56.3% in the 2011-2012 
group, and the MIC of metronidazole was the highest among all 
the studied antibiotics (8-256 μg/mL). Levofloxacin resistance 
rates decreased slightly from 26.8% in 2009-2010 to 23.3% in 
2011-2012. This finding is consistent with that reported in a pre-
vious domestic study (resistance rates decreased from 26.3% to 
22.5%) [18, 19]. The continuous increase in levofloxacin resis-
tance warrants the use of rescue therapy based on the results of 
antimicrobial susceptibility tests. Although differences in resis-
tance rates to the 5 antibiotics in the 2 study periods failed to 
reach statistical significance, increases in the resistance to clar-
ithromycin and metronidazole were identified. Moreover, multi-
drug resistance for 2 or more antibiotics increased from 16.9% 
(12/71) in 2009-2010 group to 23.4% (22/94) in the 2011-2012 
group, but there was no statistical significance (P <0.082).
 The overall eradication rate in patients who received first-line 
therapy with clarithromycin and amoxicillin was 75.8% (50/66), 
ranging from 78.1% in 2009-2010 to 73.5% in 2011-2012 (data 
not shown). The eradication rate for clarithromycin-resistant 
Table 2. Comparison of multi-drug resistance over 2 time periods*
Types of multi- 
   drug resistance
N of strains (%)
2009-2010 2011-2012
MET+LEV 8 (11.3) 8 (8.5)
CLA+MET - 3 (3.2)
CLA+LEV 2 (2.8) 3 (3.2)
AMX+MET - 2 (2.1)
CLA+MET+LEV - 6 (6.4)
AMX+MET+LEV 1 (1.4) -
CLA+AMX+MET+LEV 1 (1.4) -
*Isolates were defined as resistant to clarithromycin (CLA), amoxicillin (AMX), 
metronidazole (MET), and levofloxacin (LEV), when the MICs were ≥1, ≥1, 
≥8 and ≥1 µg/mL, respectively.
Table 3. Effects of antibiotic resistance on Helicobacter pylori eradi-
cation
First-line treatment
Clarithromycin Amoxicillin   
N of patients*
2009-2012
Eradication (%)
Success Failure
Susceptible Susceptible 58 46 (79.3) 12 (20.7)
Susceptible Resistant   1     1 (100.0)  -
Resistant Susceptible   7   3 (42.9)   4 (57.1)
Second-line treatment
Tetracycline Metronidazole
N of patients†
2009-2012
Eradication (%)
Success Failure No record
Susceptible Susceptible 8 4 (50%) 2 (25%) 2 (25%)
Susceptible Resistant 8 2 (25%) 2 (25%) 4 (50%)
Isolates were defined as resistant to clarithromycin, amoxicillin, tetracycline 
and metronidazole when the MICs were ≥1, ≥1, ≥4 and ≥8 µg/mL, re-
spectively. An eradication regimen included *first-line treatment with PPI, 
clarithromycin, and amoxicillin, and †second-line treatment with bismuth, 
tetracycline, and metronidazole.
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strains (42.9%, 3/7) was significantly lower than that for the clar-
ithromycin-susceptible strains (79.7%, 47/59) (P <0.001). These 
results indicate that resistance to clarithromycin is a critical factor 
in the effectiveness of eradication with the first-line regimen.
 Complete eradication rate was only 79.3% in strains suscep-
tible to both clarithromycin and amoxicillin with first-line therapy 
(Table 3). Thus failure rate of 20.7% may be attributable to 
problems with patient compliance; however, a more extensive 
follow-up survey is needed to confirm it. Eradication was suc-
cessful in 6 of 16 patients, who received second-line therapy in-
cluding tetracycline and metronidazole; second-line therapy 
failed in 4 patients, and data were unavailable for the remaining 
6 patients. Previous treatment histories of the 16 patients in the 
second-line treatment group were as follows: clarithromycin 
treatment for eradication of H. pylori, 2 patients; treatment for 
liver cirrhosis, 1 patient; and poor compliance, 1 patient. Spe-
cific histories were unavailable for the remaining 12 patients. Al-
though failure of eradication is generally linked to antibiotic resis-
tance, increase in antibiotic resistance does not always correlate 
with decrease in eradication rates; therefore, further studies are 
required to identify other factors affecting eradication rates.
 In conclusion, the effectiveness of eradication using first-line 
therapy with clarithromycin and amoxicillin decreased, especially 
in the clarithromycin-resistant group, and clarithromycin resis-
tance was considered crucial for the eradication of H. pylori. This 
result suggested that eradication of H. pylori is greatly dependent 
on periodic monitoring of antimicrobial susceptibility, which is 
necessary for selection of an appropriate antibiotic regimen.
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